Table 2.

Effect of deficiencies in IFN-γ versus cytolytic pathways on the frequency of chronic allograft vasculopathy. Control groups were re-listed for purpose of comparison.

Group	Donor	Recipient	Treatment	Frequency of CAV
1*	C3H	B6.rag−/−	α-H2k	5/6
2			α-H2k + α- IFN-γ	1/6
3**	C3H	B6.rag−/−γc−/−	No Rx	0/5
4***			α-H2k + B6 wild-type NK cells	6/6
5			α-H2k + B6.IFN-γ−/− NK cells	0/8
6			α-H2k + B6.pfp−/− NK cells	4/6
7	C3H.lpr	B6.rag−/−γc−/−	α-H2k + B6 wild-type NK cells	6/8
8			α-H2k + B6.pfp−/− NK cells	0/6

^*Same as Group 2 in Table 1

^**Same as Group 3 in Table 1

^***Same as Group 5 in Table 1